Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI watchdog aims to catch unsafe medical recommendations before they reach patients

NCT ID NCT07718893

Knowledge-focused Sponsor: Waymark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests CITE, a tool that checks AI-generated care plans against a library of medical evidence to flag unsafe or unsupported recommendations. Researchers will compare CITE-assisted care plans to those made with standard AI safety measures or by clinicians alone. The study involves 240 Medicaid primary care patients and focuses on how accurately CITE identifies safety hazards and how many alerts it generates for clinicians.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CITE evidence-grounding retrieve-and-verify layer
What this could lead to
If successful, CITE could help reduce medical errors by catching unsafe or unsupported recommendations in AI-generated care plans.
What could go wrong
This is a small, early-stage trial with 240 participants, so results may not apply broadly. The tool may flag too many false alarms, overwhelming clinicians.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: 1. Age 18 years or older. 2. Medicaid-enrolled and attributed to a participating Waymark primary care site. 3. Primary care encounter that requires clinical reasoning (not administrative-only). 4. English-language clinical documentation. EXCLUSION CRITERIA: 1. Age less than 18 years. 2. Hospice or palliative-care-exclusive care plan. 3. Administrative-only or pharmacy-only encounter that does not surface a clinical decision to the supervising clinician. 4. Encounter where the supervising clinician is the principal investigator. 5. Enrollment in a competing AI-safety study within the prior 90 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical decision support are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical decision support Patient safety Quality of health care

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.